JP2012136542A5 - - Google Patents

Download PDF

Info

Publication number
JP2012136542A5
JP2012136542A5 JP2012045015A JP2012045015A JP2012136542A5 JP 2012136542 A5 JP2012136542 A5 JP 2012136542A5 JP 2012045015 A JP2012045015 A JP 2012045015A JP 2012045015 A JP2012045015 A JP 2012045015A JP 2012136542 A5 JP2012136542 A5 JP 2012136542A5
Authority
JP
Japan
Prior art keywords
seq
rna molecule
sequence
composition
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012045015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012136542A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012136542A publication Critical patent/JP2012136542A/ja
Publication of JP2012136542A5 publication Critical patent/JP2012136542A5/ja
Pending legal-status Critical Current

Links

JP2012045015A 2004-09-10 2012-03-01 ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法 Pending JP2012136542A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60857404P 2004-09-10 2004-09-10
US60/608,574 2004-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007531467A Division JP2008512500A (ja) 2004-09-10 2005-09-12 ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2012136542A JP2012136542A (ja) 2012-07-19
JP2012136542A5 true JP2012136542A5 (enExample) 2013-05-30

Family

ID=36060681

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007531467A Withdrawn JP2008512500A (ja) 2004-09-10 2005-09-12 ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法
JP2012045015A Pending JP2012136542A (ja) 2004-09-10 2012-03-01 ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007531467A Withdrawn JP2008512500A (ja) 2004-09-10 2005-09-12 ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法

Country Status (5)

Country Link
US (4) US20090170794A1 (enExample)
EP (1) EP1793835A4 (enExample)
JP (2) JP2008512500A (enExample)
IL (1) IL190114A0 (enExample)
WO (1) WO2006031901A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170794A1 (en) 2004-09-10 2009-07-02 Somagenics Inc. Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
JP4054844B2 (ja) * 2005-01-28 2008-03-05 株式会社 ハプロファーマ 副作用のないＲＮＡｉ医薬
EP1979480A2 (en) * 2005-09-12 2008-10-15 Somagenics, Inc. Inhibition of viral gene expression using small interfering rna
AU2007344641B2 (en) * 2007-01-16 2014-05-22 The University Of Queensland Method of inducing an immune response
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
JP5149528B2 (ja) * 2007-03-30 2013-02-20 学校法人東京医科大学 Ｃ型肝炎ウイルスの複製を制御するマイクロｒｎａ
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
WO2010030396A2 (en) * 2008-09-15 2010-03-18 Stanford University Novel shrna gene therapy for treatment of ischemic heart disease
EP2352744B1 (en) 2008-10-15 2016-09-21 Somagenics, Inc. Short hairpin rnas for inhibition of gene expression
EP2379083B1 (en) * 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
CN102803516A (zh) * 2009-06-19 2012-11-28 联邦科学与工业研究机构 病毒试验
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
DK2561078T3 (en) * 2010-04-23 2019-01-14 Cold Spring Harbor Laboratory NEW STRUCTURALLY DESIGNED SHRNAs
EP2631291B1 (en) * 2010-10-22 2019-05-15 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
US20120308642A1 (en) * 2011-05-27 2012-12-06 Xavier University Of Louisiana Inhibiting hepatitis c viral replication with sirna combinations
US9593331B2 (en) 2011-11-02 2017-03-14 Osaka City University Double-stranded nucleic acid molecule for gene expression control
DK2817287T3 (da) 2012-02-24 2019-01-02 Arbutus Biopharma Corp Trialkyl kationisk lipid og metoder til anvendelse deraf
DK2853597T3 (en) 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
US10695548B1 (en) * 2013-02-14 2020-06-30 Transderm, Inc. Gene silencing in skin using self-delivery siRNA delivered by a meso device
US10208309B2 (en) * 2014-04-04 2019-02-19 Bioneer Corporation Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
EP3377630A4 (en) 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
EP3411481A4 (en) 2016-02-02 2020-02-26 Olix Pharmaceuticals, Inc. TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS USING ANGPT2 AND PDGFB TARGETED RNA COMPLEXES
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE
EP4121018A4 (en) 2020-03-17 2024-07-03 Genevant Sciences Gmbh CATIONIC LIPIDS FOR LIPID DNANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLA CELLS
CN117479963A (zh) 2020-12-18 2024-01-30 盖纳万科学有限公司 Peg脂质和脂质纳米粒子
CN118922401A (zh) 2022-01-31 2024-11-08 盖纳万科学有限公司 用于脂质纳米颗粒的可电离阳离子脂质
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
JPH10503364A (ja) * 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
ES2386775T3 (es) * 2001-07-23 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para la inhibición mediada por ARNi de la expresión génica en mamíferos
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US7294504B1 (en) * 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2397062B (en) * 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
WO2004027030A2 (en) * 2002-09-18 2004-04-01 Isis Pharmaceuticals, Inc. Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
JP4228071B2 (ja) * 2003-04-09 2009-02-25 独立行政法人産業技術総合研究所 Ｃ型肝炎ウイルスのタンパク質合成及び／又はｃ型肝炎ウイルスの複製を抑制することができる二本鎖オリゴヌクレオチド
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
EP1672064A4 (en) * 2003-09-22 2006-12-20 Riken EFFICIENT METHOD FOR GENERATING AN INVERTED REPEAT DNA STRUCTURE
US20050164210A1 (en) * 2004-01-23 2005-07-28 Vivek Mittal Regulated polymerase III expression systems and related methods
US20090170794A1 (en) 2004-09-10 2009-07-02 Somagenics Inc. Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
US20060142228A1 (en) 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
EP2352744B1 (en) * 2008-10-15 2016-09-21 Somagenics, Inc. Short hairpin rnas for inhibition of gene expression

Similar Documents

Publication Publication Date Title
Swaminathan et al. MicroRNAs and HIV-1 infection: antiviral activities and beyond
Bivalkar-Mehla et al. Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system
Carbonell et al. Multi‐targeting of viral RNAs with synthetic trans‐acting small interfering RNAs enhances plant antiviral resistance
HRP20190995T1 (hr) LIJEČENJE HBV-a
EA201391394A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
Alabi et al. High‐throughput sequence analysis of small RNA s in grapevine (V itis vinifera L.) affected by grapevine leafroll disease
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
Mollaie et al. RNAi and miRNA in viral infections and cancers
JP2012223202A5 (enExample)
RU2019100094A (ru) МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
JP2016116520A5 (enExample)
JP2014527401A5 (enExample)
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
WO2006121464A3 (en) Compositions for treating respiratory viral infections and their use
JP2008283975A5 (enExample)
WO2013030176A3 (en) Live attenuated influenza virus
NZ604094A (en) Double stranded rna compounds to rhoa and use thereof
JP2013531967A5 (enExample)
WO2013162350A3 (en) Circular antiviral rna
CN115820638B (zh) 一种抑制水禽源禽呼肠孤病毒复制的外源性人工miRNA及其应用
Hemida et al. Exploiting the therapeutic potential of microRNAs in viral diseases: expectations and limitations
Wang et al. Pathogenic roles of m6A modification in viral infection and virus-driven carcinogenesis
JP2010265270A5 (enExample)
JP2010270119A5 (enExample)
Liu et al. In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide